Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.34 +0.7%	$5.81	$1.76 ▼ $8.59	$743.43M	-0.49	1.11 million shs	1.13 million shs
ATAI atai Life Sciences	$3.23 +15.8%	$2.26	$1.03 ▼ $3.35	$647.09M	1.44	3.14 million shs	14.83 million shs
IKT Inhibikase Therapeutics	$1.84 -3.2%	$1.90	$1.12 ▼ $4.20	$136.79M	0.92	279,311 shs	93,530 shs
TBPH Theravance Biopharma	$11.25 -3.2%	$10.42	$7.44 ▼ $11.88	$562.50M	-0.02	257,612 shs	144,416 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-1.78%	+12.04%	+55.35%	+108.04%	+290.57%
ATAI atai Life Sciences	+3.33%	+2.20%	+25.68%	+89.80%	+74.38%
IKT Inhibikase Therapeutics	+2.15%	-5.00%	+9.20%	+0.26%	+27.52%
TBPH Theravance Biopharma	-0.26%	+1.40%	+9.62%	+34.80%	+17.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.4059 of 5 stars	4.5	1.0	3.2	2.5	0.6
ATAI atai Life Sciences	3.2004 of 5 stars	3.8	4.0	2.4	1.7	0.6
IKT Inhibikase Therapeutics	1.2122 of 5 stars	3.3	1.0	0.0	0.0	0.6
TBPH Theravance Biopharma	1.7126 of 5 stars	3.3	0.0	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	40.89% Upside
ATAI atai Life Sciences	3.50	Strong Buy	$9.00	178.64% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	253.26% Upside
TBPH Theravance Biopharma	2.67	Moderate Buy	$16.60	47.56% Upside

Current Analyst Ratings Breakdown

Latest IKT, AMLX, TBPH, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	8.51	N/A	N/A	$2.40 per share	3.48
ATAI atai Life Sciences	$1.86M	347.34	N/A	N/A	$0.69 per share	4.68
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
TBPH Theravance Biopharma	$64.38M	8.74	N/A	N/A	$3.57 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
TBPH Theravance Biopharma	-$56.42M	-$1.18	N/A	32.14	N/A	-89.38%	-32.37%	-16.48%	8/4/2025 (Estimated)

Latest IKT, AMLX, TBPH, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.43	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ATAI atai Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	TBPH Theravance Biopharma	-$0.12	N/A	N/A	N/A	$16.04 million	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
ATAI atai Life Sciences	0.08	4.07	4.07
IKT Inhibikase Therapeutics	N/A	0.85	0.85
TBPH Theravance Biopharma	N/A	4.77	4.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ATAI atai Life Sciences	28.41%
IKT Inhibikase Therapeutics	3.81%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
ATAI atai Life Sciences	26.80%
IKT Inhibikase Therapeutics	7.30%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
TBPH Theravance Biopharma	110	50.00 million	46.55 million	Optionable

IKT, AMLX, TBPH, and ATAI Headlines

Recent News About These Companies

Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60

July 17 at 3:41 AM | americanbankingnews.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 10,000 Shares of Stock

July 16 at 7:18 PM | marketbeat.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16 at 10:05 AM | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen

July 14, 2025 | americanbankingnews.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 12, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Downgraded to "Hold" Rating by Wall Street Zen

July 12, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst Upgrade

June 27, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG Research

June 27, 2025 | marketbeat.com

TBPH Theravance Biopharma, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

June 26, 2025 | prnewswire.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" Rating

June 21, 2025 | marketbeat.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of Stock

June 5, 2025 | insidertrades.com

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

June 3, 2025 | zacks.com

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

June 2, 2025 | marketwatch.com

Theravance hands off the last of its Trelegy royalties to GSK for $225M

June 2, 2025 | fiercepharma.comF

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...

June 2, 2025 | gurufocus.com

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...

June 2, 2025 | gurufocus.com

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

June 2, 2025 | prnewswire.com

Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine

May 21, 2025 | investing.com

Theravance Biopharma to Participate in an Upcoming Investor Conference

May 13, 2025 | prnewswire.com

Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Collegium Pharmaceutical (COLL) and Theravance Biopharma (TBPH)

May 11, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, AMLX, TBPH, and ATAI Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.34 +0.06 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$8.29 -0.05 (-0.60%)

As of 04:15 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

atai Life Sciences NASDAQ:ATAI

$3.23 +0.44 (+15.77%)

Closing price 04:00 PM Eastern

Extended Trading

$3.24 +0.02 (+0.46%)

As of 04:36 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Inhibikase Therapeutics NYSE:IKT

$1.84 -0.06 (-3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.85 +0.01 (+0.54%)

As of 04:02 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Theravance Biopharma NASDAQ:TBPH

$11.25 -0.37 (-3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$11.24 -0.01 (-0.09%)

As of 04:04 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time